Gloucester raises $29 million


Gloucester Pharmeceuticals Inc., (Cambridge, Mass) raised $29 million in a series D round led by new investor Novo A/S. Existing investors Apple Tree Partners; ProQuest Investments; Prospect Venture Partners; and Rho Ventures also participated. 

Gloucester's romidepsin is under FRA review to treat cutaneous T cell lymphoma (CTCL) with a Nov.12 PDUFA date. The agency's Oncologic Drugs Advisory Committee will discuss the NDA for the histone deacetylase (HDAC) inhibitor on Sept.2. Novo's Thomas Dyrberg will join Gloucester's board.